TABLE 1

Final 20 suggested BEAT-PCD consensus statements included in the infection prevention and control for primary ciliary dyskinesia (PCD) statements

No.AspectStatementConsensus %E-survey voters
1DM“The BEAT-PCD network suggests to culture on selective media for Pseudomonas aeruginosa routinely in every airway secretion sample#10018
2DM“The BEAT-PCD network suggests that all PCD Centres have access to bacterial typing”10014
3DM“The BEAT-PCD network suggests to culture airway secretion samples# from patients at least 4 times annually”94.418
4DM“The BEAT-PCD network suggests to culture for NTM at least annually and in addition at any unexplained deterioration of lung function”92.914
5DM“The BEAT-PCD network suggests routine bacterial typing at first positive culture of Burkholderia cepacia92.914
6DM“The BEAT-PCD network suggests the use of modified Leeds criteria [5] when defining chronicity of Pseudomonas aeruginosa83.318
7IT“The BEAT-PCD network suggests that treatment of NTM relies on 1) Pulmonary symptoms and 2) Nodular or cavitary processes on chest radiograph and/or bronchiectasis with small nodules on HRCT scan and 3) Positive culture results from at least two separate airway secretion samples# or positive culture results from at least one bronchial wash or lavage or mycobacterial histological findings in either transbronchial or lung biopsy material together with positive microbiological culture according to 2020 ATS/IDSA criteria” [27]10018
8IT“The BEAT-PCD network suggests that cultured Pseudomonas aeruginosa is treated regardless of symptoms and microscopy”10018
9IT“The BEAT-PCD network suggests that Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus (MSSA) are treated, if the patient is symptomatic”94.418
10IT“The BEAT-PCD network suggests that cultured Multi-Resistant Staphylococcus aureus (MRSA) is treated regardless of symptoms and microscopy”8614
11IT“The BEAT-PCD network suggests that cultured Burkholderia cepacia complex is treated regardless of symptoms and microscopy”83.318
12S“The BEAT-PCD network suggests that patients with Pseudomonas aeruginosa infection should be segregated in outpatient and in-patient settings”10018
13S“The BEAT-PCD network suggests that patients with NTM infection should be segregated in outpatient and in-patient settings”94.418
14S“The BEAT-PCD network suggests that patients with MRSA infection should be segregated in outpatient and in-patient settings”88.918
15S“The BEAT-PCD network suggests that patients with Burkholderia cepacia complex infection should be segregated in outpatient and in-patient settings”88.918
16S“The BEAT-PCD network suggests that all PCD centres have written guidelines for segregation that are adapted to the facilities of the individual centres and to the best standards”94.418
17S+“During the COVID-19 Pandemic concerning arrangements outside the hospital: The BEAT-PCD network suggests (e.g., BEAT-PCD Conferences) that if more than one patient with PCD is attending indoor events they should keep at least a 2-m distance and wear a mask regardless of infection status”93.816
e-mail
respondents
18S“The BEAT-PCD network suggests that patients with identified viral infection or ‘clinically having a cold’ should be temporarily segregated in outpatient and in-patient settings, or at least wear a mask”88.217
19S“The BEAT-PCD network suggests a cleaning procedure between patients and at the end of the day to include registered hospital-grade disinfectant/detergent”83.318
20S“The BEAT-PCD network suggests that the following bacteria do not need specific considerations regarding segregation: Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus (MSSA)”82.417

DM: diagnostic microbiology aspects; NTM: nontuberculous mycobacteria; IT: infection treatment aspects; HRCT: high-resolution computed tomography; S: segregational aspects; COVID-19: coronavirus disease 2019; MSSA: methicillin-susceptible Staphylococcus aureus. Voters: 18 PCD experts responded to the E-surveys; 16 voted by e-mail for consensus statement #15. #: Airway secretion sample defined as: sputum sample or oropharyngeal cough swab or laryngeal suction. : “Symptomatic” = increased symptoms judged at the discretion of the treating physician. +: Accepted consensus after re-evaluation due to COVID-19 pandemic. Accepted consensus was based on the decisions from an international PCD expert panel. Each proposed statement was presented for the expert panel using a Likert scale offering five possible response options: “Strongly agree”, “Agree”, “Neutral”, “Disagree”, “Strongly disagree”. Consensus for a proposed statement was defined where at least 80% agreement (“Strongly agree” or “Agree”) was obtained within the PCD expert panel.